Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel–gemcitabine chemotherapy
- 31 December 2008
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 62 (3), 356-363
- https://doi.org/10.1016/j.lungcan.2008.03.030
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancerLung Cancer, 2005
- Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized TrialJournal of Clinical Oncology, 2005
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMFBritish Journal of Cancer, 1999
- The leucocyte nadir, a predictor of chemotherapy efficacy?British Journal of Cancer, 1999
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993